Liver transplantation with a strongly positive crossmatch: Case study and literature review
- 1 September 2013
- journal article
- case report
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 19 (9) , 1001-1010
Abstract
A positive crossmatch has been associated with increased risk in liver transplantation. To study the clinical significance of preformed donor-specific human leukocyte antigen antibodies (DSAs) in liver transplantation, we reviewed patients who underwent liver transplantation with a strongly positive flow cytometry crossmatch. DSAs were evaluated with a Luminex solid phase assay. The complement-fixing ability of DSAs was tested with a complement component 1q (C1q) assay. Using an assay correlation between complement-dependent cytotoxicity crossmatch, flow cytometry crossmatch, and DSA results, we reviewed the effects of DSAs on the outcomes of our patients as well as reported cases in the literature. Five of 69 liver recipients had a strongly positive crossmatch: 4 had a positive T cell crossmatch [median channel shift (MCS) = 383.5 ± 38.9], and 5 had a positive B cell crossmatch (MCS = 408.8 ± 52.3). The DSAs were class I only in 1 patient, class I and II in 3 patients, and class II only in 1 patient. Cholestasis, acute rejection, or both were observed in 3 of the 4 patients with a positive T cell crossmatch with an MCS approximately greater than 300. The C1q assay was positive for 3 patients. Two had either persistent cholestasis or early acute rejection. One patient who was treated with preemptive intravenous immunoglobulin had an unremarkable outcome despite a positive C1q result. One of the 2 patients with a negative C1q assay experienced persistent cholestasis and early and recurrent acute rejection; the other had an unremarkable outcome. None of the patients died or lost a graft within the first year of transplantation. Our study suggests that human leukocyte antigen antibody screening, flow cytometry crossmatch MCS levels, DSA mean fluorescent intensity levels, and C1q assays may be useful in assessing the risk of antibody-mediated rejection and timely interventions in liver transplantation. Liver Transpl 19:1001–1010, 2013. © 2013 AASLD.Keywords
This publication has 40 references indexed in Scilit:
- High Mean Fluorescence Intensity Donor-Specific Anti-HLA Antibodies Associated With Chronic Rejection Postliver TransplantAmerican Journal of Transplantation, 2011
- The Significance of Donor-Specific HLA Antibodies in Rejection and Ductopenia Development in ABO Compatible Liver TransplantationAmerican Journal of Transplantation, 2011
- Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodiesLiver Transplantation, 2010
- Improved Luminex-based human leukocyte antigen-specific antibody screening using dithiothreitol-treated seraHuman Immunology, 2010
- Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant StudyHuman Immunology, 2009
- Positive Lymphocytotoxic Crossmatch Does Not Adversely Affect Survival in Living Donor Liver TransplantationDigestive Surgery, 2009
- Preformed Antibodies Detected by Cytotoxic Assay or Multibead Array Decrease Liver Allograft Survival: Role of Human Leukocyte Antigen CompatibilityLiver Transplantation, 2008
- Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: Experience of one centreTransplant Immunology, 2005
- Is presensitization relevant to liver transplantation outcome?Human Immunology, 2002
- Influence of anti-HLA antibodies and positive T-lymphocytotoxic crossmatch on survival and graft rejection in human liver transplantationJournal of Hepatology, 1996